Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

被引：1
|
作者：
Chatterjee, Anuja
Van de Wetering, Gijs
Goeree, Ron
Desbois, Anne Marie
Manzi, Patricia
Manzoor, Beenish S.
Owen, Carolyn
Sail, Kavita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Davidoff, Amy J.
    Gross, Cary P.
    Huntington, Scott F.
    BLOOD, 2020, 136 (17) : 1946 - 1955
  • [22] COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS FLUDARABINE FOR FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN COLOMBIA
    Bertwistle, D.
    Munakata, J.
    Wehler, E.
    Leyva, V
    Ariza, J. G.
    Zambrano, C.
    Gonzalez, L.
    VALUE IN HEALTH, 2013, 16 (07) : A413 - A413
  • [23] Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable
    Soini, Erkki
    Hautala, Anne
    Poikonen, Eira
    Becker, Ursula
    Kyttala, Mira
    Martikainen, Janne
    CLINICAL THERAPEUTICS, 2016, 38 (04) : 889 - 904
  • [24] ECONOMIC IMPACT OF FIXED-TREATMENT DURATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA: BUDGETIMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB FOR FIRST LINE TREATMENT OF UNFIT PATIENTS IN FRANCE
    Leblond, V
    Souihi, C.
    Ramier, J.
    Manzoor, B.
    Lepretre, S.
    VALUE IN HEALTH, 2023, 26 (12) : S185 - S185
  • [25] COST-EFFECTIVENESS OF TP53 AND IGHV BIOMARKER TESTING PRIOR TO FIRST-LINE TREATMENT WITH NOVEL AGENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA
    Vu, M.
    Degeling, K.
    Thompson, E.
    Blombery, P.
    Westerman, D. A.
    IJzerman, M.
    VALUE IN HEALTH, 2022, 25 (12) : S80 - S80
  • [26] Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
    Alrawashdh, Neda
    McBride, Ali
    Abraham, Ivo
    BLOOD, 2022, 140 : 2155 - 2156
  • [27] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [28] A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Pereira, J. M.
    Ramos, I
    Alarcao, J.
    Borges, M.
    VALUE IN HEALTH, 2019, 22 : S467 - S467
  • [29] Fixed-Duration First-Line Treatment With Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of the Fixed-Duration Cohort of the Phase 2 CAPTIVATE Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 4 - 5
  • [30] Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
    Mueller, Dirk
    Fischer, Kirsten
    Kaiser, Peter
    Eichhorst, Barbara
    Walshe, Ronald
    Reiser, Marcel
    Kellermann, Lenka
    Borsi, Lisa
    Civello, Daniele
    Mensch, Alexander
    Bahlo, Jasmin
    Hallek, Michael
    Stock, Stephanie
    Fingerle-Rowson, Guenter
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1130 - 1139
12345